Chir-258
Stage III Pancreatic Cancer
Roswell Park Cancer InstitutePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 39/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Stage III Pancreatic Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Dai, Guanghai | Phase 3 | BBB |
Irinotecan NRG Oncology | Phase 3 | BB |
Sargramostim Barbara Ann Karmanos Cancer Institute | Phase 1/2 | B |
FLUTICASONE Barbara Ann Karmanos Cancer Institute | Phase 1/2 | B |
Cediranib National Cancer Institute (NCI) | Phase 2 | B |
View all 21 →
Same molecule, other indications
Chir-258 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →